La Trobe

File(s) stored somewhere else

Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

journal contribution
posted on 2020-12-17, 22:17 authored by Verena Börger, Daniel J Weiss, Johnathon D Anderson, Francesc E Borràs, Benedetta Bussolati, David RF Carter, Massimo Dominici, Juan M Falcón-Pérez, Mario Gimona, Andrew HillAndrew Hill, Andrew M Hoffman, Dominique de Kleijn, Bruce L Levine, Rebecca Lim, Jan Lötvall, S Alex Mitsialis, Marta Monguió-Tortajada, Maurizio Muraca, Rienk Nieuwland, Anna Nowocin, Lorraine O'Driscoll, Luis A Ortiz, Donald G Phinney, Ilona Reischl, Eva Rohde, Ralf Sanzenbacher, Clotilde Théry, Wei Seong Toh, Kenneth W Witwer, Sai Kiang Lim, Bernd Giebel

STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.


Publication Date









4p. (p. 482-485)





Rights Statement

© 2020 International Society for Cell and Gene Therapy. This is an open access article under the CC BY-NC-ND license: